This CannabCo Pharmaceutical Corp. profile is part of a paid investor education campaign.*

Overview

CannabCo Pharmaceutical Corp. is a Canadian-based full-service cannabis company with operations in Brampton, Ontario. The company has received its confirmation of readiness status from Health Canada to become a licensed producer and is currently building out its pilot facility in the Brampton area.

The company is dedicated to establishing itself as a leader in top quality affordable pharmaceutical grade Cannabis supply and cutting-edge research contributing to the growing needs of the Cannabis industry.

CannabCo will employ the most advanced cultivation, processing and packaging technologies with a focus on quality at reduced costs using Pharmaceutical methodology within a GMP environment.

CannabCo intends to use an enhanced technology known as PHOENIX for its cultivation initiatives, achieving high productivity and significantly lower cost at under $.50 per gram. The company intends to launch extraction initiatives as well as enter the oils, extracts and consumable markets upon completion of its 17,500-square-foot pilot facility. The facility is being built to EU GMP standards allowing access to the underserviced global pharmaceutical market.

CannabCo Company Highlights

• PHOENIX technology that can consistently produce pharmaceutical-grade cannabis at costs of under $.50 per gram indoors.
• 17,500-square-foot pilot facility is underway expected to produce 5,000 kilograms of cannabis annually.
• The expansion cultivation facility is expected to produce over 165,000 kilograms per annum.
• The company is at confirmation of readiness with Health Canada.